Royal Eaton
Pulmonary Disease · Saint Louis, MONPI 1780675264
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 283 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by GSK at 29.3% of the total. Reporting peaked in 2019 at $1,716 and has fallen 98.7% since, to $22 in 2024.
Across 283 payments — averaging $14.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$712
- Boehringer Ingelheim$573
- Jazz Pharmaceuticals Inc.$368
- Mylan Specialty L.p.$195
- Grifols USA, LLC$175
- plus $872 from 16 others
What the payments were for
- Food & beverage$4,094100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 110 | $1,200 |
| AstraZeneca | 39 | $712 |
| Boehringer Ingelheim | 38 | $573 |
| Jazz Pharmaceuticals Inc. | 23 | $368 |
| Mylan Specialty L.p. | 11 | $195 |
| Grifols USA, LLC | 10 | $175 |
| Regeneron Healthcare Solutions, Inc. | 7 | $157 |
| Genentech USA, Inc. | 9 | $123 |
| Sunovion Pharmaceuticals Inc. | 7 | $85 |
| Sanofi | 4 | $72 |
| Harmony Biosciences LLC | 4 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Merck | 3 | $54 |
| Shire North American Group Inc | 2 | $45 |
| Paratek Pharmaceuticals, Inc. | 2 | $39 |
| Bayer | 2 | $38 |
| Gilead | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| United Therapeutics Corporation | 2 | $23 |
| Resmed Corp | 1 | $20 |
| Pfizer | 1 | $12 |
| Novartis | 1 | $11 |
How this compares
$4,094 in reported general payments places this provider in the 60th percentile of 295 pulmonary disease providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 11 | $99 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Saint Louis
- Derek ByersSaint Louis$835K
- Alexander ChenSaint Louis$679K
- Joseph OjileSaint Louis$538K
- Edward CharbekSaint Louis$372K
- Marin KollefSaint Louis$264K
- Praveen ChennaSaint Louis$255K
- Murali ChakinalaSaint Louis$172K
- Janet LeeSaint Louis$143K
- Ali SadoughiSaint Louis$87K
- Ramsey HachemSaint Louis$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.